Protocol I6T -MC-AMAR (a)  
 
A Safety, Tolerability, and Pharmacokinetic Study of Injections of LY3074828 Solution Using 
Investigational 1- mL Pre -filled Syringes and Investigational 2 -mL Autoinjector in Healthy 
Subjects  
 
[STUDY_ID_REMOVED] 
 
Approval Date: 13 -Sep-2018 
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 1
LY3074828Protocol I6T-MC-AMAR(a)
A Safety , Tolerability , and Pharmacokinetic Study  of 
Injection s of LY3074828 Solution Using Investigational 
1-mL Pre-filled Sy ringe sand Investigational 
2-mLAutoinjector in Healthy  Subjects
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
LY3074828 , unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may con tain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject t o Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY3074 828
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electr onically Signed and Approved by Lilly : 11 June 2018
Amendm ent (a) Electronically Signed and Approved by Lilly
on approval date provided below .
Approval Date: 13-Sep-2018 GMT
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 2
LY3074828Table of Contents
A Safety , Tolerability , and Pharmacokinetic Study  of 
Injections of LY3074828 Solution Using Investigational 
1-mLPre-filled Sy ringes and Investigational 
2-mLAutoinjector in Healthy  Subjects
Section Page
Protocol  I6T-MC-AMAR(a) A Safety, Tolerabilit y, and Pharmacokinetic 
Study  of Inject ions of LY3074828 Solut ion Using Invest igational 
1-mL Pre -filled Syringes and Invest igational 2 -mLAutoinjector in 
Healthy Subjects ................................ ................................ ................................ ................. 1
Table of Contents ................................ ................................ ................................ ........................ 2
1. Protocol  Synopsi s................................ ................................ ................................ ................ 7
2. Schedule of Act ivities................................ ................................ ................................ ....... 10
3. Introduction ................................ ................................ ................................ ...................... 14
3.1. Study  Rati onale ................................ ................................ ................................ ............ 14
3.2. Background ................................ ................................ ................................ .................. 14
3.3. Benefit/Risk Assessment ................................ ................................ .............................. 16
4. Object ives and Endpo ints................................ ................................ ................................ ..17
5. Study  Design ................................ ................................ ................................ ..................... 18
5.1. Overall Design ................................ ................................ ................................ ............. 18
5.2. Num ber of Participants ................................ ................................ ................................ .19
5.3. End of Study  Definit ion................................ ................................ ............................... 19
5.4. Scientific Rationale for Study  Design ................................ ................................ ........... 19
5.5. Justification for Dose ................................ ................................ ................................ ...19
6. Study  Popul ation................................ ................................ ................................ ............... 21
6.1. Inclusio n Cri teria................................ ................................ ................................ .......... 21
6.2. Exclusio n Cri teria................................ ................................ ................................ ........ 23
6.3. Lifest yle and/or Dietary Requirements ................................ ................................ ......... 25
6.3.1. Meals and Dietary  Restri ctions................................ ................................ ............. 25
6.3.2. Caffeine, Alcoho l, and Tobacco ................................ ................................ ........... 26
6.3.3. Activity................................ ................................ ................................ ................ 26
6.3.4. Bloodand Plasma Donation ................................ ................................ ................. 26
6.4. Screen Failures ................................ ................................ ................................ ............. 26
7. Dosing Regimens ................................ ................................ ................................ .............. 27
7.1. Dosing Regimens Administered ................................ ................................ ................... 27
7.1.1. Packaging and Labeling ................................ ................................ ....................... 28
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 3
LY30748287.2. Method of Treatment Assignment ................................ ................................ ................ 28
7.2.1. Selection and Timing o f Doses ................................ ................................ ............. 28
7.3. Blinding ................................ ................................ ................................ ....................... 29
7.4. Dose Modificat ion................................ ................................ ................................ ........ 29
7.5. Preparati on/Handling/Storage/Accountabilit y................................ ............................... 29
7.6. Treatment Compliance ................................ ................................ ................................ .29
7.7. Concomitant Therapy ................................ ................................ ................................ ...29
7.8. Treatment after the End of the Study ................................ ................................ ............ 30
8. Discontinuati on Cri teria ................................ ................................ ................................ ....31
8.1. Discontinuati on from Study  Treatm ent................................ ................................ ......... 31
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects ................................ .............. 31
8.2. Discontinuati on from the Study ................................ ................................ .................... 31
8.3. Subjects Lost to Follow -up................................ ................................ ........................... 31
9. Study  Assessments and Procedures ................................ ................................ ................... 32
9.1. Efficacy Assessments ................................ ................................ ................................ ...32
9.2. Adverse Events ................................ ................................ ................................ ............ 32
9.2.1. Serious Adverse Events ................................ ................................ ........................ 33
9.2.1.1. Adverse Device Effects ................................ ................................ .................. 34
9.2.1.2. Adverse Events of Special Interest ................................ ................................ ..34
9.2.1.3. Suspected Unexpected Serious Adverse React ions................................ .......... 34
9.2.2. Com plaint Handling ................................ ................................ ............................. 34
9.3. Treatment of Overdose ................................ ................................ ................................ .35
9.4. Safety................................ ................................ ................................ ........................... 35
9.4.1. Laboratory  Tests ................................ ................................ ................................ ..35
9.4.2. Vital Signs................................ ................................ ................................ ........... 35
9.4.3. Electrocardi ogram s................................ ................................ .............................. 36
9.4.4. Other Tests ................................ ................................ ................................ ........... 36
9.4.4.1. Tuberculosis Test ing................................ ................................ ....................... 36
9.4.4.2. Inject ion Duration Assessments ................................ ................................ ......36
9.4.4.3. Inject ion-site Assessments ................................ ................................ .............. 37
9.4.4.4. Bleeding Assessment ................................ ................................ ...................... 37
9.4.4.5. Inject ion-site Pain ................................ ................................ ........................... 37
9.4.5. Safety Moni toring ................................ ................................ ................................ 37
9.4.5.1. Hepati c Safet y................................ ................................ ................................ 37
9.4.5.2. Moni toring of Hy persensi tivity Reacti ons................................ ....................... 38
9.5. Pharmacokinet ics................................ ................................ ................................ ......... 38
9.5.1. Bioanalysis ................................ ................................ ................................ ........... 38
9.6. Pharmacodynamics ................................ ................................ ................................ ......39
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 4
LY30748289.6.1. Immunogenicit y Assessments ................................ ................................ .............. 39
9.7. Genet ics................................ ................................ ................................ ....................... 39
9.8. Biomarkers ................................ ................................ ................................ ................... 40
9.9. Health Economics ................................ ................................ ................................ ........ 40
10. Statistical Considerations and Data Analysis ................................ ................................ .....41
10.1. Sample Si ze Determinat ion................................ ................................ .......................... 41
10.2. Popul ations for Analyses ................................ ................................ .............................. 41
10.2.1. Study  Parti cipant Disposit ion................................ ................................ ............... 41
10.2.2. Study  Parti cipant Characterist ics................................ ................................ .......... 41
10.3. Statistical Analyses ................................ ................................ ................................ ......41
10.3.1. Safety Analyses ................................ ................................ ................................ ....42
10.3.1.1. Clinical Evaluation of Safet y................................ ................................ .......... 42
10.3.1.2. Statistical Evaluat ion of Safet y................................ ................................ ....... 42
10.3.1.2.1. Inject ion-site Pain ................................ ................................ ..................... 42
10.3.1.2.2. Durati on of  Inject ion................................ ................................ ................. 42
10.3.1.2.3. Inject ion-site Assessments ................................ ................................ ........ 42
10.3.1.2.4. Statistical Evaluat ion of Other Safet y Param eters ................................ ......43
10.3.2. Pharmacokinet ic Analyses ................................ ................................ .................... 43
10.3.2.1. Pharmacokinet ic Parameter Estimat ion................................ ........................... 43
10.3.2.2. Pharmacokinet ic Statistical Inference ................................ ............................. 43
10.3.3. Pharmacodynamic Analyses ................................ ................................ ................. 43
10.3.4. Pharmacokinet ic/Pharmacodynamic Analyses ................................ ...................... 43
10.3.5. Evaluat ion of Immunogenicit y................................ ................................ ............. 43
10.3.6. Data Review During the Study ................................ ................................ ............. 44
10.3.7. Interim Analyses ................................ ................................ ................................ ..44
11. References ................................ ................................ ................................ ........................ 45
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 5
LY3074828List of Tables
Table Page
Table AMAR.1. Object ives and Endpo ints................................ ................................ ....... 17
Table AMAR.2. Dosing Regimens Administered ................................ ............................. 27
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 6
LY3074828List of Appen dices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................ ................................ 46
Appendix 2. Clinical Laboratory  Tests ................................ ................................ ........ 50
Appendix 3. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 51
Appendix 4. Hepati c Moni toring Tests for Treatme nt-Emergent Abnormalit y............ 54
Appendix 5. Blood Sam pling Summary ................................ ................................ ......55
Appendix 6. Protocol  Amendment I6T -MC-AMAR(a) Summary:  A Safet y, 
Tolerabilit y, and Pharm acokinetic Study  of Inject ions of 
LY3074828 Solut ion Using Invest igational 1 -mL Pre -filled 
Syringes and Invest igational 2 -mLAutoinjector in Healthy 
Subjects ................................ ................................ ................................ ..56
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 7
LY30748281.Protocol Synopsis
Title of Study:
A Safety, Tolerability, and Pharmacokinetic Study of Injections of LY3074828 Solution Using Investigational 
1-mLPre-filled Syringes and Investigational 2-mLAutoinjector in Healthy Subjects
Rationale: 
Study I6T -MC-AMAR (AMAR) will assess the pharmacokine tics (PK), safety and tolerability of, and pain 
associated with ,a 250 -mg subcutaneous (SC) dose of LY3074828 solution formulation administered using a n 
investigational manual pre-filled syringe (PFS) or an investigational autoinjector (AI).  The administr ation by AI 
will be a 1x2-mL 125 -mg/mL fast -speed injection and the administration by PFS will be 2 x1-mL 125 -mg/mL 
injections.  Both methods of administration will be evaluated at 3 different injection sites (arm, thigh, and abdomen ) 
in order to expand the options for administration in patient use .  The study will provide data to bridge PFS 
administration (as used in Study I6T-MC-AMAE [AMAE]) of LY3074828, a monoclonal antibody, with the 
investigational AI device planned for use in subsequent studies an d patient use.
Objective s/Endpoints:
Objectives Endpoints
Primary
To evaluate the PK after administration of 
250-mg doses of LY3074828 solution 
formulation using 2 x1-mL PFS and 
1x2-mL AI injections in healthy subjects.
To assess the safety and tolerability of 
LY3074828 in healthy subjects.
To assess pain associated with LY3074828 
PFS and AI SC administrations in healthy 
subjects at 3 different injection sites (arm, 
thigh, and abdomen) .The primary PK endpoints will be the C max, 
AUC(0 -tlast), and AUC(0 -∞) of LY3074828.
Incidence of TEAEs.
VAS pain score.
Abbreviations:  AI = autoinjector; AUC(0 -∞) = area under the concentration versus time curve from time zero to 
infinity ; AUC(0 -tlast) = area under the concentration versus time curve from time zero to time t, where t is the 
last sample with a measurable concentration; C max = maximum observed drug concentration; PFS = pre -filled 
syringe; PK = pharmacokinetic; SC = subcutaneous; TEAE =treatment -emergent adverse event; VAS = visual 
analog scale.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 8
LY3074828Summary of Study Design:
Study I6T -MC-AMAR (AMAR) is a single -center, randomized, parallel -arm, open -label, Phase 1 single -dose study 
of LY3074828 solution formulation in healthy subjects.  Pharmacokinetics, safety and tolerability of, and pain 
associated with, 250-mg SC doses administered using a PFS or an investigational AI at 3different injection sites 
will be evaluated.
Subjects will be randomized to a 2 x1-mL PFS arm, thigh, or abdomen administration or a 1 x2-mL AI arm, thigh, 
or abdomen administration.  Subjects will report to the clinical research unit (CRU) on Day -1 and will remain at the 
CRU until the scheduled p rocedures have been completed on Day 2.  Study drug will be administered by 
investigative site staff by SC injection per the randomization scheme in the morning of Day 1 after an overnight fast.  
Subjects will be followed for 12 weeks following dose admini stratio n.
Safety and tolerability will be assessed by clinical laboratory tests, vital sign measurements, 12 -lead 
electrocardiograms, recording of adverse events and product complaints, physical examinations/medical 
assessments, immunogenicity, and injecti on-site assessments.  Pain assessments will be made using aninjection -site 
pain visual analog scale (VAS).
Dosing Regimen Arms and Duration for an Individual Subject :  
Subjects will receive a 250 -mg SC dose of LY3074828 and will be randomized to 1 of 6 dosing regimen arms:
Test 1:  250 mg LY3074828 solution formulation, 1 x 2 -mL 125 -mg/mL AI injection administered in the 
arm
Test 2:  250 mg LY3074828 solution formulation, 1 x 2 -mL 125 -mg/mL AI injection administered in the 
thigh
Test 3:  250 mg LY3074828 solution formulation, 1 x 2 -mL 125 -mg/mL AI injection administered in the 
abdomen
Reference 1:  250 mg LY3074828 solution formulation, 2 x 1 -mL 125 -mg/mL PFS injections administered 
in the arm
Reference 2:  250 mg LY3074828 solution formulation, 2 x 1 -mL 1 25-mg/mL PFS injections administered 
in the thigh
Reference 3:  250 mg LY3074828 solution formulation, 2 x 1 -mL 125 -mg/mL PFS injections administered 
in the abdomen
Total duration of the study for each subject will be approximately 16 weeks (screening period ≤28 days, residential 
period of 2 days, and outpatient follow -up period of 12 weeks).
Number o f Subjects :
A total of approximately 66subjects who fulfill the eligibility criteria will be randomized to 1 of 6 dosing regimen 
arms , with 11subjects randomized to each arm to ensure completion of 10subjects in each.  A subject’s study 
participation is considered as complete if he/she receives the study drug as per the protocol requirements and 
completes all activities up to and including at l east Day 57.  A maximum of 2 subjects per arm may be replaced if 
multiple subjects do not complete the study.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 9
LY3074828Statistical Analysis:
The area under the concentration versus time curve (AUC) from time zero to infinity (AUC[0 -∞]), AUC from time 
zero to time t , where t is the last sample with a measurable concentration (AUC[0 -tlast]), and maximum observed 
drug concentration (C max) will be log -transformed and analyzed using a linear fixed -effects model.  The model will 
include device and injection location as fixed effect s.  The dosing regimen differences between Test and Reference 
armswill be back -transformed to present the ratios of geometric least squares (LS) means and the corresponding 
90% confidence interval (CI).
The time to C max (tmax) of LY3074828 betwe en Test and Reference arms will be analyzed using a Wilcoxon rank 
sum test.  Estimates of the median difference, 90% CIs, and p -values from the Wilcoxon rank sum test will be 
calculated.
Additional PK analyses may be conducted if deemed appropriate. 
Alinear fixed -effects model will be used to analyze the post -injection pain VAS score s.  The model will include 
device and injection location as fixed effect s.  The LS means and differences in LS means will be presented along 
with the corresponding 90% CI.
Safety  parameters will be listed and summarized using standard descriptive statistics.
Additional safety and tolerability analyses will be performed if warranted upon review of the data.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 10
LY30748282.Schedule of A ctivities
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 11
LY3074828Study Schedule Protocol I6T-MC-AMAR
Screening Days Comments
Procedure ≤28 days -1 1 24
±1d8
±1d11
±1d15
±2d22
±2d29
±2d43
±2d57
±3d71
±3d85/ED
±3d
Informed c onsent X
Review / confirm 
inclusion/exclusion 
criteriaX X Any time prior to dosing.
Subject admission to 
CRUX
Subject discharge 
from CRUX
Outpatient visit X X X X X X X X X X X
Randomization XSubjects randomized to 1 of 6dosing regimen
arms.
LY3074828 injection X Doses administered by investigative site staff.
Stopwatch recording XStopwatch is the source for injection duration
capture for PFS and AI .
Medical history X
Weight, height, and 
BMIX
Vital signs:  blood 
pressure, pulse rate, 
temperature (hour)X X 0, 6 24 X XX X X X X XTimes with respect to start of dosing.  Single 
ECGs to be collected.  Zero -hour collection 
within 30 minutes before dosing.  Time 
allowance for 6 -and 24 -hour time points:  ±30 
and ±90 minutes, respectively.  For vital sign 
assessments, temperature need only be 
included at predose and when clinically 
indicated.12-lead ECG (hour) X 0 24 X
Physical examination 
/ medical assessmentX X X X XFull physical examination/medical assessment 
at screening.  Symptom -directed phy sical 
examination/medical assessment at all other 
time points, and as deemed necessary by the 
investigator.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 12
LY3074828Screening Days Comments
Procedure ≤28 days -1 1 24
±1d8
±1d11
±1d15
±2d22
±2d29
±2d43
±2d57
±3d71
±3d85/ED
±3d
AE review X X X X X X X X X X X X X XAE only after signing ICF.  Product complaints 
and device -related AEs collected as 
appropriate.
QuantiFERON ®-TB 
Gold test X
Serology X See Appendix 2 for test details.
Ethanol test and urine 
drug screenX XMay be repeated at the discretion of the 
investigator.  E thanol test may be measured in 
blood, urine ,or expired air .  See Appendix 2
for test details.
FSH / serum 
pregnancy testX X X X XSerum pregnancy tests for all female subjects
at screening .  For all women who are 
considered to be postmenopausal, FSH should 
be drawn at screening to confirm 
postmenopausal status as defined in inclusio n 
criterion [1 b].  Women with confirmed 
postmenopausal status at screening are 
exempted from further pregnancy tests dur ing 
the study .  See Appendix 2 for test details.
Clinical chemistry, 
hematology, and 
urinaly sisX X X X X X See Appendix 2 for test details.
Creatine 
phosphokinaseX X X
Injection -site 
assessment for 
erythema, induration, 
pruritus, and edema
(hour)0, 0.25 X X XTimes with respect to start of dosing.  
Zero-hour assessments within 1minute 
following injection.  Time allowance for 
0.25-hour assessment is ±5 minutes.  
Additional assessments performed if deemed 
necessary by the investi gator.
Injection -site 
bleeding assessment 
(hour)0Time with respect to start of dosing.  
Zero-hour assessment within 1 minute 
following injection.  
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 13
LY3074828Screening Days Comments
Procedure ≤28 days -1 1 24
±1d8
±1d11
±1d15
±2d22
±2d29
±2d43
±2d57
±3d71
±3d85/ED
±3d
Pain assessment 
(VAS) (minutes)1, 5, 15Timepoints are minutes post -injection as 
follows: within 1 minute ofthe end of 
injection, 5 (±1.5), and 15(±2) minutes .  For 
1-mL PFS, the second injection will be 
administered 20 min utes(±2) after first 
injection .
LY3074828 
pharmacokinetic 
sampling (hour)0, 2, 6 24 X X X X X X X X X XTimes with respect to start of dosing.  
Zero-hour collection immediately (within 
15minutes) before dosing.  Time allowance 
for 2 -, 6-, and 24 -hour time points:  ±15, ±30, 
and ±90 minutes, respectively.
Immunogenicity 
samplePredose X X X X LY3074828 antibody sample.
Pharmacogenetics 
sampleX
Abbreviations:   AE=adverse event; AI = autoinjector; BMI = body mass index; CRU = clinical research unit; d=day; ECG =electrocardiogram; ED =early 
discontinuation; FSH = follicle -stimulating hormone; ICF =informed consent form ;PFS = pre -filled syringe; TB =tuberculosis; VAS = visual analog scale.
Site should schedule activities as appropriate.  In cases where several study procedures are scheduled at the same time, foll ow this order of priority for 
procedures:  pharmacokinetic samples, clinical laboratory tests, immunogenicity sample, stored sample, ECG, vital signs, pain assessment, injection -site 
assessment, such that pharmacokinetic sample collection occurs as close t o the nominal collection time as possible.  Procedures specified as predose may be 
performed within 2 hours from planned dosing.  
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 14
LY30748283.Introduction
3.1. Study Rationale
Study  I6T-MC-AMAR (AMAR) will assess the pharmacokinet ics (PK), safet y and tol erability 
of, and pain associated with a 250 -mg subcutaneous (SC) dose of LY3074828 so lution 
formulation administered using a n invest igationalmanual pre-filled syringe (PFS) or an 
investigat ional autoinjector (AI).  The administration by  AI will  be a 1 x2-mL125-mg/mL 
inject ion and the administration by PFS will be 2 x1-mL 125 -mg/mL injections.  Both methods 
of administrati on will be evaluated at 3 different inject ion sites (arm, thigh, and abdom en) in 
order to expand the options for administration in patien t use .  The study  will provide data to 
bridge PFS administration (as used in Study I6T-MC-AMAE [AMAE]) of LY3074828, a 
monoclonal antibody ,with the invest igational AI device planned for use in subsequent studies 
and pat ient use.
3.2. Background
LY3074828 is a humanized immunoglobulin G4 -variant m onocl onal ant ibody  that i s directed 
against the p19 subunit of interleukin -23 (IL -23) and does not bind interleukin -12.  LY3074828 
is being developed for the treatment of autoimmune diseases in which the IL -23 pathway  is 
thought to have a significant pathogenic role.  Neutralizat ion of IL -23 wi th an ant i-mouse IL -23 
surrogate antibody  (directed against the p19 subunit) significant ly reduced the development of 
arthri tis and inhibited ileal inflammat ion in a mouse model of spondyloarthropathy  with bowel  
inflammat ion (Ruutu et al. 2012).  Addit ionally , neutralizat ion of IL -23 si gnificant ly reduced the 
disease score in the relapsing -remitt ing experimental autoimmune encephalo myelitis (mult iple 
sclerosi s-like) m odel in mice.  Anti-IL-23 ant ibody also demonstrated some efficacy in 
preclinical arthritis models, depending on the timing of intervent ion (Cornelissen et al. 2013).  
Psori asis is one of the most commo n immune -mediated chronic inflammatory  skin diseases, 
affect ing abou t 2% to 3% of the world's populat ion (Nestle et al. 2009; Perera et al. 2012).  A 
typical organ -specific T -cell-driven inflammatory  disease, psoriasis had been considered a 
Thelper (Th) 1 -type skin disease for decades unt il a new Th population, Th17, was ident ified 
(Lew et al . 2004; Steinman 2007; Weaver et al. 2007).  However, substant ial clinical and basic 
research observat ions now suggest that the IL -23/Th17 axis is essent ial in the pathogenesis o f 
psori asis (Di  Cesare et al . 2009).  Treatment of psoria sis wi th biologic therapy , parti cularly wi th 
those agents targeting the IL -23/Th17 axis, has demo nstrated clinical activit y in pat ients with 
psori asis (Crow 2012).
As of the Invest igator’s Brochure (IB) cutoff date, there have been approximately  
819partic ipants in studies o f LY3074828.  These include 245 patients wi th psori asis, 
248patients wi th ulcerat ive colit is, 85 patients wi th Crohn’s di sease, and 241 healt hy subjects 
who were exposed to either placebo or LY3074828 at single doses ranging fro m 5 to 1 200mg 
and mult iple doses up to a maximum o f 1000 mg intravenous (IV) and 300 mg SC.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 15
LY3074828Data from the clinical pharmaco logy devel opment program  are available for 2completed 
Phase 1 studi es(Studi esI6T-MC-AMA A[AMA A]and I6T-MC-AMA E[AMA E])and 4
ongoing Phase 1 studi es(Studi esI6T-JE-AMAD [AMAD ], I6T-MC-AMAL [AMAL ],
I9O-MC-AABA [AABA ],andI6T-MC-AMA Q[AMA Q]).
No deaths, serious adverse events (SAEs), or discont inuat ions due to an adverse event (AE) have 
been reported in any o f the Phase 1 studi es.
In the com pleted Study AMAA, a total of 82 treatment -emergent AEs (TEAEs) were reported by  
37subjects.  The most commo nly reported TEAEs in this study  were nasopharyngit is and 
headache.  There were no drug -related TEAEs of National Cancer Inst itute Commo n 
Term inology Cri teria for Adverse Events Grade 2 or higher reported in Study AMAA.  
In the com pleted Study  AMAE, the incidence of TEAEs was similar between the 250 mg 
LY3074828 lyophilized formulat ion and the 250 mg LY3074828 PFS so lution formulation, wi th 
a notably  higher number of TEAEs reported by  subjects who received 500 mg LY3074828 
solution formulation.  The mo st commo n TEAEs related to study  treatm ent were events 
occurring at the site of inject ion, including injection -site reacti on (ISR)and inject ion-site 
hemorrhage.  Across all formulat ions, the m ajority of TEAEs reported during the study  were 
mild, wi th only 1TEAE that was m oderate in severi ty but not related to study  drug.  
There were no obvious trends in the pattern of AEs across studies apart from ISRs .  Injection-site 
pain, of short duration (usually hours), has been reported in both the completed and o ngoing 
clinical pharmaco logy studi es.  In Study AMAA, inject ion-site pain (related to study  drug) was 
reported in 3 out of 5 healt hy subjects receiving 120 mg LY3074828 via SC administration; 
however, no infusion react ions were reported.  Preliminary  data from Studi esAMAE and AMAL 
showed that most ISRs were mild or moderate in severit y, with severe inject ion-site pain 
reported in 2% of ISRs in the 250 -mg SC test formulat ion group.    
Treatment -emergent ant i-drug antibodies (TE -ADAs) developed in 3 of 33 patients with 
psori asis receiving single IV doses of LY3074828 in Study  AMAA.  The TE -ADAs were 
observed in the 120 -and 350 -mg dose groups.  The earliest time po int at whi ch TE -ADAs were 
detected was Day  22, whi ch was the first postdose time point at which immunogenicit y was 
assessed and, where present, TE -ADAs were generally st ill detectable at Day 85.  The highest 
anti-drug ant ibody  (ADA) ti ter observed was 1:320.  None of the healt hy subjects (n=5) who 
received 120 mg SC LY3074828 developed TE -ADAs. 
Treatment -emergent ADAs developed (by Days 29 and 85, respectively ) in 2 of 6 subjects 
following single SC doses of 200 mg LY3074828 in Study  AMAD; however, ti ters were ≤1:160.  
Based on preliminary  data for this study , a similar proporti on of  subjects develo ped TE -ADAs 
following IV doses of LY3074828 (9 of 26) compared to SC doses, mostly occurring at Day 85. 
However, the highest titer of 1:5120 (declining to 1:320 after eight months) occurred i n a 
Japanese subject who received 200 mg IV LY3074828.  
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 16
LY30748283.3. Benefit /Risk Assessment
Based on LY3074828 nonclinical and preliminary clinical data, there are no anticipated risks 
requi ring m onitoring bey ond those for a ty pical  humanized m onoclonal antibody  in human 
studi es.  As wi th other immunom odulatory  therapies, LY30748 28 m ay increase the ri sk of 
developing an infect ion or m ay exacerbate an existing serious infect ion.  These may  include 
opportunist ic infect ions and react ivation of latent infect ions, such as tuberculosis (TB) and 
hepat itis B.  Subjects will therefore be s creened for hepat itis B/C, human immunodeficiency 
virus (HIV), and TB.  Immuno modulatory  therapi es may increase the risk of malignancies; 
however, due to only single doses of LY3074828 being administered in this study , it is not 
considered necessary  to m onitor for such effects.  
Based on available data fro m Studi esAMAA and AMAD, TE-ADAs have been observed in 2 of 
the 11 healthy subjects that received SC doses of LY3074828; however, titers were ≤1:160.  In 
the 33 patients with psoriasis who received single IV doses of LY3074828, TE -ADAs were 
detected in 3 subjects (Study AMAA).
No clinically  significant safet y or tol erabilit y concerns have been identified in pat ients or healthy 
subjects to date for LY3074828 up to the highest doses given (single 1200 -mg IV doses and 
2400 -mg SC doses).  
Healthy subjects are not expected to derive any benefit from participating in studies wit h 
administration of LY3074828.  
As thi s study  will use PFS and AIs, device -based risks will be evaluated.  Possible device -based 
risks include local effects such a s pain at the injectio n sites fro m either the needle or the solut ion 
entry  into the SC ti ssue, swelling, ery thema, bleeding, and bruising.  These risks are mit igated by  
training o f investigative site staff on proper inject ion te chniques.  Sy stemic effects may include 
sweat ing, feeling faint, or fever, as a sign of infect ion.  
More informat ion about the known and expected benefits, risks, SAEs, and reasonably 
anticipated AEs of LY3074828 are found in the IB.
More informat ion abou t the known and expected benefits, risks, SAEs, and reasonably  
anticipated AEs of the AI is found in the device IB.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 17
LY30748284.Objectives and Endpoints
Table AMAR .1shows the objectives and endpo ints of the study .
Table AMAR .1. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the PK after administration of 
250-mg doses of LY3074828 solution 
formulation using 2 x1-mL PFS and 1 x2-mL 
AI injections in healthy subjects.
To assess the safety and tolerability of 
LY3074828 in healthy subjects.
To assess pain associated with LY3074828 PFS 
and AI SC administrations in healthy subjects 
at 3different injection sites (arm, thigh, a nd 
abdomen).The primary PK endpoints will be the C max, 
AUC(0 -tlast), and AUC(0 -∞) of LY3074828.
Incidence of TEAEs.
VAS pain score.
Abbreviations:  AI = autoinjector; AUC(0 -∞) = area under the concentration versus time curve from time zero to 
infinity ;AUC(0 -tlast) = area under the concentration versus time curve from time zero to time t, where t is the 
last sample with a measurable concentration; C max = maximum observed drug concentration; PFS = pre -filled 
syringe; PK = pharmacokinetic; SC = subcutaneo us; TEAE =treatment -emergent adverse event; VAS = visual 
analog scale.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 18
LY30748285.Study  Design
5.1. OverallDesign
Study  I6T-MC-AMAR (AMAR) is a single -center, randomized, parallel -arm, open -label, 
Phase 1 single -dose study  of LY3074828 so lution formulation in healt hy subjects.  
Pharmacokinet ics, safet y and tol erabilit y of, and pain associated with ,250-mg SC doses 
administered using a PFS or AI at 3 different injectio n sites will be evaluated.
Screening Period ( ≤28 days):   Subjects will be evaluated for study eligibili ty ≤28 days pri or to 
enrollment.
Residential Period (2 days):   A total of approximately 66subjects who fulfill the eligibilit y 
criteria will be rando mized to 1 of 6 dosing regimen arms, with 1 1subjects rando mized to each 
arm to ensure com pletion of  10subjects in each:
Test 1:  250 mg LY3074828 so lution formulation, 1 x 2 -mL 125 -mg/mL AI inject ion, 
administered in the arm
Test 2:  250 mg LY3074828 so lution formulation, 1 x 2 -mL 125 -mg/mL AI inject ion, 
administered in the thigh
Test 3:  250 mg LY3074828 so lution formulation, 1 x 2 -mL 125 -mg/mL AI inject ion, 
administered in the abdo men
Reference 1:  250 mg LY3074828 so lution formulation, 2 x 1 -mL 125 -mg/mL PFS 
inject ions targeting a 5 -to 10 -second inject ion time for each injection, administered in 
the arm
Reference 2:  250 mg LY3074828 so lution formulation, 2 x 1 -mL 125 -mg/mL PFS 
inject ions targeting a 5 -to 10 -second inject ion time for each injection, administered in 
the thigh
Reference 3:  250 mg LY3074828 so lution formulation, 2 x 1 -mL 125 -mg/mL PFS 
inject ions targeting a 5 -to 10 -second inject ion time for each injection, administered in 
the abdo men
Subjects will report to the clinical research unit (CRU) on Day  -1 and will remain at the CRU 
until the scheduled procedures have been co mpleted on D ay 2.  Study  drug will be administered 
by invest igative site staff by SC inject ion per the rando mizat ion scheme in the morning o f Day 1 
after an overnight fast.  
Outpatient Follow -up Period (12 weeks):   The follow -up peri od will include outpatient visits 
for atotal of 12 weeks (Days 4, 8, 11, 15, 22, 29, 43, 57, 71, and 85 )following dose 
administration on Day  1 to assess the PK, safet y and tol erabili ty of, and pain associated with 
LY3074828 PFS and AI administrations .  Assessment of pain at the Follow -up visi ts does not 
include visual analog scale ( VAS )score.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 19
LY3074828Safety and tol erabilit y will  be assess ed by  clinical laboratory  tests, vi tal sign measurements, 
12-lead electrocardiograms ( ECGs) , recording of AEs and product complaints (PCs) , physical 
examinat ions/med ical assessments, immunogenicity, and inject ion-site assessments.  Pain 
assessments will be made using aninject ion-site pain VAS.
5.2. Number of Participants
A total o f approximately  66subjects who fulfill the eligibilit y criteria will be rando mized to 1 of 
6dosing regimen arms, with 1 1subjects rando mized to each arm to ensure complet ion of
10subjects in each.  A subject’s study  parti cipat ion is considered as co mplete if he/she receives 
the study  drug as per the protocol requirements and completes all activi ties up to and including at 
least Day  57.  A m aximum  of 2subjects per arm may  be repl aced if mult iple subjects do not 
complete the study .
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2) for the last subject .
5.4. Scientific Rationale for Study Design
Conducting the study  in healt hy subjects mit igates t he potential confounding effects of the 
disease state and concomitant medications in pat ients.  A populat ion of h ealthy subjects is
frequently used in the assessment of bioavailabilit y of both small and large mo lecules.
Single doses of LY3074828 and the PK sampling time points have been selected to generate PK 
profiles sufficient to fulfill the study  object ives.  As the primary endpo ints of this study  are 
PK-related and are not subject to bias, it is not considered necessary  for this study  to be blinded.  
Subjects and site staff will be aware of the administration route and treatment.
A parallel -group desi gn was chosen because a crossover design is impract ical for com pounds 
that have long half -lives, such as mo noclonal  antibodies.  Addit ionally , a crossover study  design 
could confound PK data if subjects develop neutralizing ADAs.
Monoclonal  antibody  therapy  has been associ ated wi th hypersensit ivity react ions, including 
ISRs.  Follow -up details on ISRs will be co llected by the investigative site regarding the severit y, 
durati on, ty pe, and timing of the start of the event in relat ion to the start of study  drug 
administration in order to further characterize these events.
Methods of administration will be evaluated at 3 different inject ion sites (arm, thigh, and
abdo men) in order to expand the options for administration in pat ient use.  
5.5. Justification for Dose
The doses for this study  are based on the vo lume of solut ion that can be delivered by the PFS and 
AI (1 or 2mL) and the solubilit y of LY3074828 (125 mg/mL ), resul ting in a dose of 250 mg 
LY3074828.  
CCI
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 20
LY3074828Intravenous d oses up to 1200 mg and SC doses up to 2400 mg were found to be well tolerated in 
healt hy subjects in the single -dose Stud iesAMAD and AA BA.  Subcutaneous bioavailabilit y 
was approximately 40% in Study AMAA.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 21
LY30748286.Study  Population
Eligibilit y of subjects for study  enrollment will be based on the results of medical history , 
physical examinat ion, vital signs, clinical laboratory tests, and ECG.  
The nature of any condit ions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening wi ll occur up to 28 day s prior to enrollment.  Subjects who are not enrolled within 
28days of screening may  be subject ed to an addit ional medical assessment and/or clinical 
measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the f ollowing criteria at 
screening and/or enr ollment:
[1] are overtly healt hy male or female subjects, as determined by medical 
history  and physical examinat ion
[1a] male subjects:
Men, regardless of their fertilit y status, with non -pregnant wom en of childbearing 
potenti al partners m ust agree to ei ther rem ain abst inent (if this is their preferred and 
usual lifest yle) or use condoms as well as one additional highly effect ive(less than 
1% failure rate) method of contraception (such as combinat ion oral  contraceptives, 
implanted con tracepti ves, or intrauterine devices) or effect ive method of 
contraception (such as diaphragms with spermicide or cervical sponges) for the 
durati onof the study  and f or 24 weeks following dosing wit h the study  drug
oMen and their partners may  choose to use a double -barrier method of 
contraception. Barrier protection methods without concomitant use of a 
spermicide are not an effect ive or acceptable me thod of contracepti on.  
Thus, each barrier method must include use of a spermicide.  It should be 
noted, however, that the use of male and female condo ms as a 
doubl e-barrier method i s not considered acceptable due to the high failure 
rate when these barrie r methods are combined
oPeriodic abst inence ( eg, calendar, ovul ation, symptothermal, post -ovulation 
methods), declaration of abst inence just for the duration of a trial, and 
withdrawal  are not acceptabl e methods of contraception
Men wi th pregnant partners s hould use condoms during intercourse for the duration 
of the study  and f or 24 weeks following dosing wit h the study  drug
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 22
LY3074828Men should refrain fro m sperm  donat ion for the durati on of  the study  and f or 
24weeks following dosing wit h the study  drug
Men who are in exclusively same -sex rel ationships (as their preferred and usual 
lifest yle) are not required to use contraception
[1b] female subjects:
All female subjects must test negative for pregnancy  prior to ini tiation of treatm ent 
as indicated by  a negat ive seru m pregnancy  test at the screening visit . Women of 
childbearing potential must also have a negat iveserum  pregnancy test within 
24hours prior to exposure .  Women not of childbearing potential due to 
postm enopausal status must have follicle -stimulat ing hor mone >40 m IU/mL at the 
screening visit
Women of childbearing potential who are abstinent (if this is co mplete abst inence, 
as thei r pref erred and usual lifest yle) or in a same -sex rel ationship (as part of their 
preferred and usual lifest yle) must agree to either rem ain abst inent or stay in a 
same -sex rel ationship wi thout sexual relat ionships with males.  Periodic abst inence 
(eg, calendar, ovulat ion, symptothermal, post -ovulati on methods), decl aration of 
abstinence just for the duration of a trial, and wit hdrawal  are not acceptable 
methods of contraception
Otherwi se, women of childbearing potential part icipating must agree to use one 
highly  effect ive method (less than 1% failure rate) of contraception, or a 
combinat ion of 2 effect ive methods of contraception (for 12 weeks fo llowing 
dosing wit h the study  drug)
oEither one hi ghly effect ive method of contraception (such as combinat ion 
oral contraceptives, implanted con tracepti ves, or intrauterine device) or a 
combinat ion of 2 effect ive methods of contraception (su ch as male or 
female condo ms with spermicide, diaphragms wit h spermicide, or cervical 
sponges) will be used.  The subject may  choose to use a doubl e-barrier 
method of contraception.  Barrier protection methods without concomitant 
use of a spermicide are no t a reliable or acceptable method.  Thus, each 
barrier m ethod m ust include use of a spermicide.  It should be noted that the 
use of male and female condo ms as a double -barrier method is not 
considered acceptable due to the high failure rate when these meth ods are 
combined
Women not of childbearing potential may participate and include those who are: 
oinfertile due to surgical sterilizat ion (hysterectomy, bilateral oophorectomy, 
or tubal ligation) or congenital anomaly such as mullerian agenesis; or 
opostm enopausal –defined as eit her:
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 23
LY3074828A wo man at l east 50 years of age with an intact uterus, not on 
horm one therapy , who has had either:
cessat ion of menses for at least 1 y ear; or 
at least 6 m onths of spontaneous amenorrhea with a 
follicle -stimulat ing horm one > 40 m IU/mL ; or 
A wo man 55 years of age or older not on horm one therapy , who has 
had at least 6 months of spontaneous amenorrhea; or 
A wo man at l east 55 years of age with a diagnosis of menopause 
prior to starting hormone -replacement therapy
[2] are betwee n 18 and 65 y ears of age, inclusive, at time of screening
[3] have a body  mass index (BMI) of 18.0 to 32.0 kg/m 2, inclusive, at time of 
screening
[4] have clinical laboratory  test resul ts wi thin norm al reference range for the 
investigat ive site, or results with acceptable deviat ions that are judged to be 
not clinically significant by  the invest igator
[5] have venous access sufficient to allow for blood sampling as per the 
protocol
[6] are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures
[7] are able and willing to give signed informed consent
6.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment:
[8] are invest igative site personnel direct ly affiliated with this study  and thei r 
immediate families.  Immediate family is defined as a spouse, biological or 
legal guardian, child, or sibling
[9] are Lilly  empl oyees or em ployees o f Covance
[10] are currently enrolled in a clinical study  involving an invest igational 
product (IP) or any  other ty pe of  medical  research judged not to be 
scientifically or medically co mpatible wit h this study
[11] have participated in a clinical trial invo lving an IP within 30 days or 
5half-lives (whichever is lo nger) prior to screening.  If the clinical trial 
involved treatment with bio logic agents (such as monoclonal ant ibodies, 
including m arketed drugs), at least 3 months or 5 half -lives (whichever is 
longer) should have elapsed prior to Day  1
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 24
LY3074828[12] have previously completed or withdrawn fro m this study  or any  other study  
investigat ing LY3074828, and have previously received the IP
[13] have known allergies to LY3074828, related compounds, or any  
components of the formulat ion, or h istory of significant atopy
[14] have an abnormalit y in the 12 -lead ECG that, in the opinion o f the 
investigator, increases the risks associated with participat ing in the study
[15] have an abnormal blood pressure as determined by the investigator
[16] have a history  or presence of cardiovascular, respiratory , hepat ic, renal, 
gastrointestinal, endocrine, hematological, or neurological disorders 
capable of significant ly altering the absorption, metabolism, or eliminat ion 
of drugs; of const ituting a ri sk when taking the IP; or of interfering wit h the 
interpretati on of  data
[17] have known or ongoing psychiatric disorders deemed clinically  significant 
by the investigator
[18] regul arly use known drugs of abuse and/or show posit ive findings on drug 
screening
[19]show evidence of HIV infection and/or posit ive HIV ant ibodies
[20] show evidence of hepatit is C and/or positive hepat itis C ant ibody
[21] show evidence of hepatit is B and/or positive hepat itis B surface antigen
[22] are wom en who are lactating
[23] have used or intend to use over -the-counter or prescript ion medications, 
including herbal medicat ions, within 14 days pri or to dosing and for the 
durati on of  the study .  Stable doses of oral contraceptive or 
horm one-replacement therapy  are permi tted, at the dis cretion of the 
investigator
[24] have donated blood of more than 500 mL within 1 mo nth prior to screening 
[25] have an average weekly  alcohol  intake that exceeds 21 units per week 
(males) and 14 units per week (females), have a posit ive test for ethano l, or 
are unwilling to abide by  the alcohol  restri ctions described in Section 6.3.2
(1 uni t = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45mL 
of distilled spirits)
[26] have a tobacco consumpt ion of more than 10 cigarettes per day  (or 
equivalent), are unwilling to refrain fro m smoking for approximately  
1hour prior to each ECG and vital sign measurements during the study , or 
who are unwi lling to abi de by the CRU smoking guidelines described in 
Secti on 6.3.2
[27] have had symptomat ic herpes zoster within 3 mo nths of screening
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 25
LY3074828[28] show evidence of active or latent TB, as documented by  medical  history , 
examinat ion, and TB testing (negat ive [not indeterminate] 
Quant iFERON ®-TB Gol d test); or have had househo ld contact with a 
person wi th active TB, unless appropriate and documented prop hylaxis 
treatm ent has been given.  Subjects with any history  of active TB are 
excluded fro m the study , regardl ess of previ ous or current TB treatments
[29] have received live vaccine(s), including attenuated live vaccines and those 
administered intranasall y, within 8 weeks of screening, or intend to during 
the study
[30] have been treated with oral steroi ds wi thin 1 month of screening, or intend 
to during the study (mild topical steroid creams/o intments are permitted)
[31] are immunocompro mised
[32] have received treatment with bio logic agents (such as monoclonal 
antibodies) for a medical condit ion within 3 m onths or 5 half -lives 
(whichever is longer) prior to Day  1
[33] have significant allergies to humanized monoclonal antibodies 
[34] have clinically  significant m ultiple or severe drug allergies, or intolerance 
to topi cal corti costeroi ds, or severe posttreatment hypersensit ivity react ions 
(including, but not limited to, ery thema mul tiforme major, linear 
immunogl obulin A dermatosis, toxic epidermal necrol ysis, or exfo liative 
derm atitis)
[35] have had lympho ma, leukemia, or any  malignancy  within the past 5 years 
except for basal cell or squamous epithelial carcinomas of the skin that 
have been resected with no evidence o f metastati c disease for 3 y ears
[36] have had breast cancer within the past 10 y ears
[37] have excessive tattoos over the arm, thigh, or abdomen that would interfere 
with injecti on-site assessments
[38] in the opinio n of the invest igator, are unsuitable for inclusion in the study
6.3. Lifestyle a nd/or Dietary Requirements
Throughout the study, subjects may undergo medical assessment sand review of compliance with 
requirements before continuing in the study .  
6.3.1. Meals and Dietary Restrictions
Subjects will fast overnight for at least 8 hours before d osing (water is permitted).  Standard 
meals will be provided at all other times while subjects are resident at the CRU, as per the 
CRU’s policy.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 26
LY30748286.3.2. Caffeine, Alcohol, and Tobacco
Subjects will not consume caffeinated beverages (decaffeinated beverages are per mitted) while 
at the CRU, and for 12 hours prior to admissio n to the CRU.  At other times during the outpatient 
period, subj ects will be allowed to maintain their regular caffeine consumpt ion.
Alcoho l consumpt ion is not permitted while at the CRU, and for 12hours prior to each study 
visit.  At other times, alcoho l consumpt ion should be limited to 2 units per day (1 unit = 12 oz or 
360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of dist illed spirits).
Subjects who smoke will be advised to not increase their consumpt ion of tobacco products 
during the study .  Subj ects will be asked to refrain from smoking for approximately  1hour pri or 
to each ECG and vital sign measurements, and to abide by  the CRU sm oking guidelines.
6.3.3. Activity
Subjects will be a dvised to maintain their regular levels o f physical act ivity/exercise during the 
study , but to refrain from strenuous activit y from 24hours prior to each visit and 48 hours prior 
to any  visit where creatine phosphokinase testing will occur (Day  -1, Day  8,and Day 29).  While 
certain study  procedures are in progress at the site, subjects may be required to remain recumbent 
or sitting.
6.3.4. Blood and Plasma Donation
Subjects will not donate blood or plasma for 12 weeks fo llowing dosing wit h the study  drug.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay not be 
re-screened.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 27
LY30748287.Dosing Regimens
7.1. Dosing Regimens Administ ered
This study  will evaluate the PK, safet y and tol erabili ty of, and pain associated with 250 -mg SC 
doses administered using 2 x1-mL PFS sor an investigational 1x2-mL AI at 3 different 
inject ion sites .
Using the invest igational 2 -mL AI, the targeted injection duration will be approximately
5seconds.  Manual injections using the PFS should target an injection durat ion of about 5 to 
10seconds for each 1-mL inject ion to approximate the inject ion time range for the AI.  The 
second of the 2 PFS injections should be administered 20 (±2) minutes after the first injection to 
allow for collection o f 3 VAS pain score time points prior to administration of the second 
inject ion.  Approximate inject ion durations for AIs and PFSs will be obtained using a calibrated 
stopwatch and recorded in the electron ic case report form (eCRF).  
Drug and device accountabilit y records will be maintained by  the si te pharmacy .
Table AMAR .2show sthe dosing regimens for the study .
Table AMAR .2. Dosing Regimens Administered
Dosing 
RegimenPFS AI
Reference/testReference
1Reference
2Reference
3Test
1Test
2Test
3
Injection site Arm Thigh Abdomen Arm Thigh Abdomen
Product LY3074828 LY3074828
Dose 250 mg 250 mg
Concentration 125 mg/mL 125 mg/mL
Injection 
volumes2 × 1 mL
(2 mL total)1 × 2 mL
(2 mL total)
Number of 
injections2 1
Injection 
duration5 to 10 seconds per injection Approximately 5 seconds
Formulation 
and 
presentationSolution in a PFS Solution in an AI
Abbreviations:  AI = autoinjector; PFS = pre -filled syringe .
The PFSs and invest igational AIscontaining LY3074828 will be supplied fully assembled to the 
clinical site by Lilly.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 28
LY3074828Inject ions, whether administered by PFS or AI, will be given into the arm, thigh, or lower 
quadrant of the abdo men. For PFS administrations requiring 2 inject ions, subjects randomized to 
a group wi th the arm  or thi gh as the inject ion site will have both injections administered to the 
same limb ( same arm or same thigh) .  Subjects randomized to the group with the abdo men as the 
inject ion site will have the 2 PFS injections administered to separate lower quadrants (right and 
left) of the abdo men. Investigat ional product will be administered to subjects on -site by  
designated trained clinical site personnel.  
Prior to the PFS or AI inject ion, the invest igator or his/her designee will prepare the subject’s 
skin per Instructi ons for Use (IFU).  Inject ions into the arm , thigh, or abdom en will be 
administered by  invest igative site staff according to the instructions provided by the sponsor.  All 
study  inject ion sites will be marked using a template for size and with a surgical marker in order 
to identify study  injection sites for later assessments.   Further informat ion regarding SC 
administration will be included in the device IFU for the PFS and in the device IB (which 
contains IFU) for the AI .
In some cases, the site may destroy  the m aterial if, during the invest igative site select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clinical trial materials. 
7.1.1. Packaging and Labeling
LY3074828 will be supplied by the sponsor or its designee in accordance wi th current good 
manufacturing process , and labeled according to the country’s regulatory requirements.  All IPs
will be stored, inventoried, reconciled, and returned or destroy ed according to applicable 
regul ations. The fo llowing products will be supplied by  Lilly:
pre-assembled LY3074828 PFSs, 1 mL
pre-assembled invest igational LY3074828 AIs, 2mL
Each invest igational device will be individually ident ified and labeled according to US 
regul atory  requi rements for investigational devices.
7.2. Method of Treatment Assignment
Subjects will be rando mized toa 2x1-mL PFS arm, thigh, or abdomen administration or a 
1x2-mL AIarm, thigh, or abdomen administration (Table AMAR .2).
Randomization will be performed using a computer -generated randomizat ion schedule.
7.2.1. Selection and Timing of Doses
The actual  time of all dose administrations (including both the first and second of the 2 PFS 
inject ions) will be recorded in the subject ’s eCRF .
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 29
LY30748287.3. Blinding
This is an open -label study .
7.4. Dose Modification
Dose adjust ments are not permitted in this study .
7.5. Preparation/Handling/Storage/Accountability
The IPs for this study  will be:
LY3074828 in PFSs
LY3074828 in inv estigational AIs
Invest igational product will be stored refrigerated at 2°C to 8°C (36°F to 46°F) in its original 
carton to protect from light.  Invest igational product should not be frozen or shaken.  Sites will 
be required to monitor temperature of the o n-site storage condi tions of  the IP.  The investigator 
or desi gnee m ust confirm  appropriate tem perature condi tions have been maintained, as 
communicated by  sponsor, during transit for all IP received and any  discrepancies are reported 
and reso lved before u se of the study  treatm ent.
The AIs and PFSs containing LY3074828 should be allowed to warm to room temperature 
before use.  
Only participants enro lled in the study  may receive IP or study  materials, and only authorized 
site staff may supply or administer IP.  All IP should be stored in an environmentally controlled 
and mo nitored (m anual  or autom ated) area in accordance wit h the l abeled storage condit ions 
with access limited to the invest igator and authorized site staff.
The invest igator is responsible for study  treatm ent accountabilit y, reconciliat ion, and record 
maintenance (such as receipt, reconciliat ion,and final disposit ion records).
7.6. Treatment Compliance
The IP will be administered at the clinical site, and documentation of treatment administration 
will occur at the site.
7.7. Concomitant Therapy
Over -the-counter or prescript ion medications, including herbal medicat ion, are not permitted 
within 14 days prior to dosing and throughout the study .  However, stable doses of oral 
contraceptive or horm one-replacement therapy  are permi tted at the discretion of the invest igator.
Paracetamo l/acetaminophen (up to 2 g/day) is permitted at the discret ion of the invest igator , but 
shoul d be avoi ded during the 4 -hour postdose period when pain assessments are made .  
Addit ional drugs are to be avo ided during the study, unless required to treat an AE.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 30
LY3074828If the need for concomitant medicat ion arises, inclusi on or continuat ion of the subject may be at 
the discret ion of the invest igator after consultation with a Lill y clinical pharmaco logist (CP) or 
clinical research physician (CRP).  Any addit ional medicat ion used during the course of the 
study  must be docum ented.
7.8. Treatment after the End of the Study
This sect ion is not applicable for this study.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 31
LY30748288.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
Randomized subjects who discont inue the study prematurely for any reason should co mplete the 
early  discontinuat ion (ED) procedures as shown in the Schedule of Act ivities(Secti on2).  The 
reason for, and the date of discont inuat ion, will be collected for all subjects.
8.1.1. Discontinua tion of Inadvertently Enrolled Subjects
If the sponsor or i nvest igator ident ifies a subject who did not meet enrollment criteria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  CP or CRP and the invest igator 
to determine if the subject may  cont inue in the study .  If both agree i t is medically  appropriate to 
continue, the invest igator must obtain documented approval fro m the Lilly  CP or CRP to all ow 
the inadvertently enro lled subject to continue in the study.  Any subjects that are inadvertently 
enrolled will be fo llowed for safet y.
8.2. Discontinuation from the Study
Subjects will be discont inued in the fo llowing ci rcum stances:
Enrollment in any other clinical study  involving an IP or enrollment in any other type of 
medical research judged not to be scient ifically or medically co mpat ible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice
The invest igator decides that the subject should be discontinued fro m the study
The subjec t reque sts to be withdrawn from the study
Subjects who discont inue the study early will have ED procedures performed as shown in the 
Schedule of Act ivities(Secti on 2).
8.3. Subjects Lost to Follow -up
A subject will be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact subjects who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  the si te.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 32
LY30748289.Study Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the clinical laboratory tests that wi ll be perform ed for this study .
Appendix 5 provi des a summary of the maximum  number and vo lume of invasive samples, for
all sampling, during the study .
The specificat ions in this protocol for the timings of safet y and sample co llection are given as 
targets to be achieved wit hin reasonable limits.  Modificat ions may be made to the time po ints 
based upon emerging clinical informat ion.  The scheduled t ime points may be subject to minor 
alterati ons; however, the actual time must be correctly  recorded in the eCRF.  Late collection 
outsi de the st ipulated time allowances or failure to obtain samples due to clinical issues, such as 
probl ems wi th equipment, venous access, or subject default ing on a scheduled procedure, will 
not be con sidered as protocol deviations but the site will st ill be requi red to notify  the sponsor in 
writing via a file -note.
Unless otherwise stated in subsect ions below, all s amples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may be 
retained for a longer peri od, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
This sect ion isnot applicable to this study .
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subjects during the study .
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate healt h care option, 
AEs that are serious or otherwise medically important, cons idered related to the IP or the study .  
The subject should be fo llowed unt il the event resolves, stabilizes with appropriate diagnostic 
evaluat ion, or is reasonably  explained.  The frequency of follow -up evaluat ions of the AE is left 
to the di scret ion of t he invest igator.
After the informed consent form is signed, study  site personnel will record, via eCRF, the 
occurrence and nature of each subject’s preexist ing conditions.  Addit ionally , site personnel will  
record any  change in the condit ion(s) and the occ urrence and nature of any  AEs.  
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 33
LY3074828The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account 
concomitant treatment or pathologie s.  
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the IP, 
study  device ,and/or study  procedure and the AE.
Planned surgeries should not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospitalizat ion
a life -threatening experience (that is, immediate risk of dying)
persistent or sign ificant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but may jeopardize the patient or may require intervent ion to prevent 
one of the other outcom es listed in the definit ion above
when a condit ion related to the invest igational device (PFS or AI) necessitates medical or 
surgi cal interventi on to precl ude ei ther perm anent impai rment of  a body  function or 
perm anent dam age to a body  structure, th e seri ous outcom e of “requi red intervent ion” 
will be assigned.
Study  site personnel  must al ert the Lilly  CRP/CP, or i ts desi gnee, of  any SAE as soon as 
practi cally  possible.
Addit ionally , study  site personnel  must al ert Lilly  Global Patient Safet y(GPS) , or its designee, 
of any SAE wi thin 24 hours of invest igator awareness of the event via a sponsor -approved 
method.  If alerts are issued via telephone, they  are to be immediately fo llowed wi th official  
notification on study -specific SAE forms.  This 24 -hour notificat ion requirement refers to the 
initial SAE informat ion and all fo llow-up SAE inform ation.
Although all AEs are recorded in the eCRF after signing informed consent, SAE reporting to the 
sponsor begins after the subject has signed informed consent and has received IP.  However, if 
an SAE occurs after signing informed consent, but prior to receiving IP, AND is considered 
Reasonably Possibly Related to a study  procedure then it MUST be reported.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued fro m and/or com pleted the study  (the subject summary eCRF has been completed).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 34
LY3074828been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly . 
Pregnancy (maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulf ill regulatory  requi rements any  pregnancy  should be reported following the SAE 
process to collect data on the outcome for both mother and fetus.
9.2.1.1. Adverse Device Effects
Any AE believed to be related to an issue wit h the AI or PFS is considered an adverse de vice 
event.  These events must be clearly indicated as such in the eCRF, and reported to the sponsor.  
A PC shoul d also be reported.
For the purpose of this protocol, “unant icipated” adverse device effect means any  SAEalleged to 
be associ ated or related t o the device, and which has been confirmed as such by the sponsor.  The 
SAE rel atedness m ust be cl early  indicated as such in the eCRF, and reported to the sponsor 
within 24 hours of site knowledge of the event.  A PC should also be reported.
9.2.1.2. Adverse Events of Special Interest
The fo llowing AEs of special interest will be used to determine the safet y and tol erabilit y of 
LY3074828 inject ions administered by  either PFS or investigational AI in this clinical study .
Adverse events of special interest for LY30748 28 are:
infect ion
ISRs
allergic/hypersensit ivity react ions
If infections, ISRs, or allergic/hypersensit ivity reacti ons are reported, sites will provide details on 
these events as instructed on the eCRF.  Invest igators will also educate subjects about the 
symptoms of allergic/hypersensit ivity react ions and will provide instructions on dealing wit h 
these reactions.  A blood s ample will be collected when possible for any subject who experiences 
an AE of allergic/hypersensit ivity react ion during the study .
9.2.1.3. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator reports as related to IPor procedure.  Lilly  has procedures that 
will be fo llowed for the recording and expedited reporting of SUSARs that are consistent with 
global regulat ions and the associated detailed guidances.
9.2.2. Complaint Handling
Lilly co llects PCs on IPs and drug delivery systems used in clinical trials in order to ensure the 
safet y of study  participants, m onitor quali ty, and to facilitate process and product improvements.
Subjects should be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the IP or drug delivery  system  so that the si tuation can be assessed.  
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 35
LY3074828A PFS or AI that is associated with a product quality  issue or complaint must be retu rned to 
Lilly.
The invest igator or his/her designee is responsible for handling the fo llowing aspects of the PC 
process in accordance with the instructions provided for this study :
recording a complete descript ion of the PC reported and any associated AEs using the 
study -specific co mplaint form s provi ded for this purpose
faxing the completed PCformwithin 24 hours to Lilly or its designee.
If the invest igator is asked to return the product for invest igation, he/she will return a copy of the 
PCformwith the product.
9.3. Treatment of Overdose
For the purposes of this study , an overdose of LY3074828 is considered any  dose higher than the 
dose assigned through rando mizat ion.
There i s no specific antidote for LY3074828.  In the event of an ov erdose, the subject should 
receive appropriate supportive care and any AEs should be documented.
Refer to the study  drug IB for further details.
9.4. Safety
9.4.1. Laboratory Tests
For each subject , laboratory  testsdetailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Activities (Secti on2).
Lilly or i ts desi gnee will  provide the investi gator wi th the resul ts of laboratory  tests analyzed by  
a central  vendor, if a central vendor is used for the study .
9.4.2. Vital Signs
For each subject, vital sign measurements (blood pressure, pulse rate, and temperature) should be 
conducted according to the Schedule of Activit ies (Secti on 2).  Ad ditional vi tal signs m ay be 
measured during the study  if warranted.
Blood pressure and pulse rate should be measured after at least 5 minutes supine.
If orthostatic measurements are required, subjects should be supine for at least 5 minutes and 
stand for a t least 2 minutes.
If the subject feels unable to stand, supine vital signs only  will be recorded. 
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.  
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 36
LY30748289.4.3. Electrocardiograms
For each s ubject, a single 12-lead digital ECG will be collected according to the Schedule of 
Activities (Section 2).  El ectrocardi ograms m ust be recorded before collecting any blood 
samples.  Subjects must be supine for at least 5 minutes before ECG collect ion and remain 
supine but awake during ECG collect ion.  El ectrocardi ograms m ay be obtained at addit ional 
times ,when deemed clinically necessary .  All ECGs recorded shoul dbe stored at the 
investigat ional site.
Electrocardiograms will be interpreted by  the investi gator or qualified designee at the site as 
soon after the time o f ECG collect ion as possible, and ideally while the subject is st ill present, to 
determine whether the subject meets entry  criteria at the rel evant visit(s) and for immediate 
subject management, should any  clinically rel evant findings be i dentified.  
If a clinically significant finding is ident ified (including, but not limited to, changes in QT/QTc 
interval  from baseline) after enrollment, the investigator will determine if the subject can 
continue in the study .  The invest igator, or qualified designee, is responsible for determining if 
any change in subject management is needed, and must document his/h er review of the ECG 
printed at the time of co llection.  
Any clinically  significant findings from ECGs that result in a diagnosis and that occur after the 
subject receives the first dose of the IP should be reported to Lilly, or its designee, as an AE via
eCRF.
9.4.4. Other Tests
9.4.4.1. Tuberculosis Testing
Subjects will be tested as indicated in the Schedule of Act ivities (Section 2) for evidence of 
active or latent TB using the QuantiFERON -TB Gol d test.  If the test is indeterminate, 1 retest i s 
allowed.  If the retest is indeterminate, the subject will be excluded fro mthe study .
Subjects who have had househo ld contact with a person with active TB must be excluded unless 
appropriate and documented prophylaxis treatment for TB has been co mpleted.
Subjects with any history  of active TB are excluded fro m the study , regardl ess of previous or 
current TB treatments.
9.4.4.2. Injection Duration Assessments
Inject ion duration will be measured by a calibrated stopwatch by  qualified trained study  staff.  
The durati on of  injecti on for the PFS will be defined as the time between when the plu nger rod is 
pressed down and when all o f the LY3074828 solution is injected.  The duration of inject ion for 
the AI will be defined as the time between the first audible click after the injection button is 
pressed and the last audible click, which indicates that the needle has retracted and the inject ion 
is co mplete.  
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 37
LY30748289.4.4.3. Injection -site Assessments
Inject ion site finding s(including ery thema, induratio n, pruritus, and edema) will be captured on 
a separate ISR form,asindicated in the Schedule of Act ivities (Se ction 2).
Data from injection site evaluat ions (including pain) which are recorded as a result of specific 
questionnaire /s will not be reported as AEs. If the investigator determines that the ISR is
clinically significant or if it is an unso licited event (vo lunteered by  subject), the event will be 
captured i n the subject ’s eCRF as an AE .  
If an ISRis deemed to be an AE, the ISRform will be used to capture specific informat ion about 
this react ion (eg, degree and area of erythema).
9.4.4.4. Bleeding Assessment
All injecti on si tes will  be observed at the times indicated in the Schedule of Act ivities (Section 2) 
by the investigator or designee, and the presence of visible bleeding will be recorded on the 
eCRF.  A bandage may be placed on the inject ion site after assessment.
9.4.4.5. Injection -site Pain
Pain measurements will be quant ified using the 100 -mm validated VAS pain score for all 
subjects, whether or not they  report i njecti on pain.  The VAS is a well -validated tool 
(Williamso n and Hoggart 2005) to assess inject ion-site pain; i t is presented as a 1 00-mm line 
anchored by  verbal descriptors, usually “no pain” and “worst possible pain.”  The subject will be 
asked to rate any  pain at the injection site on a scale of 0 to 100 mm on the line immediately  
(within 1minute) fo llowing the inject ion and at the time points listed in the Schedule of 
Activities (Section 2).
9.4.5. Safety Monitoring
The Lilly CPor CRP /scientist will mo nitor safet y data throughout the course of the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly CPor 
CRP will periodically review the fo llowing data:
trends in safety  data
laboratory  analytes
AEs, including monitoring of incidence of any  nature of any  infect ions, and ISRs
PCs
When appropriate, the Lilly CP or CRP will consult with the funct ionally  independent GPS 
therapeuti carea physician, GPS device physician, or GPS clinical research scientist.
9.4.5.1. Hepatic Safety
If a study  subject experiences elevated alanine aminotransferase (ALT) ≥3× upper limit of 
norm al (ULN), al kaline phosphatase (ALP) ≥2× ULN, or elevated total bilirubin (TBL) 
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 38
LY3074828≥2×ULN, liver tests (Appendix 4) should be repeated within 3 to 5 days including ALT, 
aspartate aminotransferase, ALP, TBL, direct bilirubin, gamma -glutamyl transferase, and 
creatine phosphokinase to confirm the abnormalit y and to determine if it is increasing or 
decreasing.  If the abnormalit y persists or worsens, clinical and laborat ory monitoring shoul d be 
initiated by  the invest igator based on consultation with the Lilly CP or CRP.  Monitoring should 
continue until levels normalize and/or are returning to approximate baseline levels. 
Addit ional safet y data should be co llected if 1 or more of  the f ollowing condit ions occur: 
elevation of serum  ALT to ≥5×ULN on 2or more consecut ive blood tests
elevated serum  TBL to ≥2×ULN (except for cases of known Gilbert’s syndrome)
elevation of serum  ALP to ≥2×ULN on 2 or more consecut ive blood tests 
hepat ic event considered to be an SAE.
9.4.5.2. Monitoring of Hypersensitivity Reactions
There i s a risk of systemic hypersensit ivity react ions wit h any  biological  agent, including acute 
anaphylaxis and delayed hypersensit ivities to LY3074828.  Symptoms and signs that may occur 
as part of these hypersensit ivity react ions include, but are not limited to: fever, chills, jo int and 
muscle pain, rash, itching, urticaria, dizziness, headache, throat irritation, and shortness of 
breath.  Less co mmo nly, life -threatening anaphylactic react ions may occur, which may include 
vascular collapse and/or respiratory  com promise.
All subjects will be closely mo nitored for si gns and symptom s of hypersensit ivity react ions 
following administration of the study  drug, and appropria te medical care shoul d be provi ded.  
Hypersensi tivity react ions will be evaluated by examinat ion of TEAEs and SAEs, and through 
the use of a fo llow-up form which will be com pleted by  the invest igator.  Potential 
hypersensit ivity events will be evaluated by a Lilly CRP based on accepted criteria (Sampson et 
al. 2006 ).
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities (Secti on 2), venous blood samples 
of approximately  2mL each will be co llected to determine the serum concentrations of 
LY3074828.  A maximum o f 3 sam ples m ay be collected at addit ional time points during the 
study  if warranted and agreed upon between both the invest igator and sponsor.  Instructions for 
the collect ion and handling of blood samples will be provided by the sponsor.  The actual date 
and time (24 -hour cl ock time) of each sampling will be recorded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aborator y approved by  the sponsor and stored at a facilit y 
designated by  the sponsor.  Concentrations of LY3074828 will be assayed using a validated 
enzyme -linked immunosorbent assay.  
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 39
LY3074828Bioanaly tical samples collected to m easure IP concentrations will be retained for a m aximum  of 
1 year fo llowing last subject visit for the study .  During this t ime, samples remaining after the 
bioanalysis may  be used for exploratory  metabo lism or exploratory analyses such as 
bioanalyt ical assa y validati on or cross -validation exercis es.
9.6. Pharmacodynamic s
9.6.1. Immunogenicity Assessments
Blood sam ples f or immunogenicit y testing will  be collected to determine ant ibody  producti on 
against LY3074828, as specified in the Schedule of Act ivities (Secti on 2).  Addit ional samples 
may be collected if there is a possibilit y that an AE is immunol ogically  mediated.  If addi tional 
immunogenicit y testing samples are taken, matching PK sample co llections will also be required.  
Immunogenicit y will be assessed by  a validated assay  designed to detect ADAs in the presence 
of the IP.  Ant ibodies may be further characterized and/or evaluated for their abilit y to neutralize 
the activit y of the IP.  
A risk -based approach will be used to monitor subjects who develop TE -ADAs during and 
following treatm ent wi th LY3074828.
Subjects will have ADA sampling at baseline (predose) and on Days 15, 29, 57, and 85 (see 
Schedule of Act ivities [Secti on 2]).
Subjects who have clinical sequelae that are considered poten tially related to the presence of 
TE-ADA may be asked to return for addit ional follow-up testing.
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local  regulat ions and institutional review boards (IRBs) allow, at a facilit y selected by  
the sponsor.  The duration allows the sp onsor to respond to future regulatory  requests related to 
the IP.  Any  samples remaining after 15 years will be destroy ed.
9.7. Genetics
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule o f 
Activities (Secti on 2), where l ocal regulat ions allo w.  
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable exposure or response to 
LY3074828 and to investigate genetic variants thought to play  a rol e in autoimmune and 
inflammatory  diseases.  Assessment of variable response may include evaluat ion of AEs or 
differences in efficacy.  
All samples will be coded with the subject number.  These samples and any  data generated can 
be linked back to the subject only by the inves tigative site personnel.  
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local  regulat ions and/or IRB impose shorter time limit s, for the study  at a f acility 
selected by  Lilly or i ts desi gnee.  This retention period enables use of new techno logies, response 
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 40
LY3074828to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the development of LY3074828 or after LY3074828 is commercially available.  
Molecular t echno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, exist ing approaches include who le geno me or exome 
sequencing, geno me wide association studies, multiplex assays, and candidate gene studi es.  
Regardless of techno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion.
9.8. Biomarker s
This sect ion is not applicable for this study.
9.9. Health Economics
Thissection is not applicable for this stud y.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 41
LY307482810. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
Approximately 66 subjects will be enrolled with a target of 60 subjects com pletingthe study  
(10completers per treatment). 
Data from AMAL (2 x1-mL dose sof 250 mgLY3074828 ) and AMAE (2 x1-mL PFS dose sof 
250mgLY3074828 ) studi es showed that the geometric coefficient of variation ranged fro m 55% 
to 40% for the PK measurements ( ie, area under the concentration versus time curve [ AUC ]from 
time zero to infinit y [AUC (0-∞)], AUC from time zero to time t, where t is the last sample with a 
measurable concentration [ AUC (0-tlast)],and maximum observed drug concentration [ Cmax]).
Thus, the geometric coefficient of variat ion was assumed to be 55% when calculat ing precisio n.
A sample size of 60 subjects will provide a precision (ie, half-width of 90% of confidence 
interval  [CI]with a coverage probabilit y of 90%) , in log scale, of approximately  0.48 f or 
thegeom etric means rati o of reference versus test for AUC(0 -∞), AUC(0 -tlast), and C max. 
Equivalently, there is a 90% probabilit y that the distance between the lower limit of the 90% CI 
and the point estimate of the geometric means rat iois not larger than 38%.
Subjects who are randomized but not administered treatment, or subjects (maximum of
2subjects per dose regimen arm ) that are administered treatment but do not have PK and ADA 
samples co llected up to and including Day 57, may be replaced to ensure that approximately 
10subjects from each treatment arm may co mplete the study .
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description o f subject disposit ion will be provided at the end of the study . 
10.2.2. Study Participant Characteristics
The subject’s age, sex, weight, BMI, height, race/subrace, and other demographic data will be 
summarized by  dosing regimen and overall.
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  or its 
designee.
Pharmacokinet ic analyses will be conducted on the full analysis set.  This set includes all data 
from all randomized subjects receiving the dose of LY3074828 with evaluable PK data.  Safet y 
analyses will be conducted for all subjects receiving a dose of LY3074828, whether or not they  
completed all  protocol  requi rements .
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 42
LY3074828Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  Study  
resul ts may be pool ed wi th the resul ts of other studies for populat ion PK analysis purposes to 
avoid issues with post -hoc analyses and inco mplete di sclosures of a nalyses.  
No adj ustments for multiple com parisons will be made.
10.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All IP and protocol procedure AEs and PCs will be listed, and if the frequency o f events allows, 
safet y data will be summarized using descriptive methodol ogy.
The incidence of symptoms for each treatment will be presented by  severi ty and by associ ation 
with IP as perceived by the invest igator.  Symptoms reported to occur prior to study entry will be 
distinguished from those reported as new or incre ased in severit y during the study .  Each 
symptom  will be classified by  the m ost sui table term fro m the medical regulatory  dictionary.
The number of IP -and device -related SAEs and any  related PCs will  be reported.
10.3.1.2. Statistical Evaluation of Safety
10.3.1.2.1. Injection -site Pain
The intensit y of pain at theinject ion site within 1 minute of the end of inject ionand 5minutes 
after the end of the inject ionwill be evaluated, as reported by  the subject and m easured 
according to the 0 -to 100 -mm VAS.  Assessments will also be performed at 15 minutes 
post-inject ion; however, the primary  endpoint swill be the 1-and 5 -minute assessment s. For 
1-mL PFS, the second inject ion will be administered 20 (±2) minutes after the first inject ion.
Descript ive statistics will be used to s ummarize the intensit y of pain at each t ime point.
A linear fixed -effects m odel will be used to analyze the post -inject ion pain VAS score s.  The 
model will include device and inject ion location as fixed effect s.  The l east squares (LS) means 
and difference s in LS means will be presented along with the corresponding 90% CI.  The 
distribut ion of the data will be explored prior to analysis to determine whether data 
transformation is required.  It is possible that the pain scores will be 0 ,so if the distribut ion of  
the data implies that a log -transformat ion is required then the score may be updated to 
log(VAS+1) to allow for the inclusion o f the 0 values in the analysis.
10.3.1.2.2. Duration of Injection
The durati on of  the inject ion (measured in seconds) will be summariz ed for each drug delivery  
device for each inject ion site .
10.3.1.2.3. Injection -site Assessments
The incidence of the following AEs will be listed and summarized for each drug delivery device 
for each inject ion site : erythema, indurat ion, pruritus, and edema .  Occurrence of bleeding will 
be listed.   
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 43
LY307482810.3.1.2.4. Statistical Evaluation of Other Safety Parameters
Other safet y param eters that will be assessed include clinical laboratory  param eters and vital 
signs.  The parameters and changes fro m baseline (predose) ,where appropriate, will be listed 
and summarized using standard descriptive statist ics.  Addit ional analyses will be performed if 
warranted upon review of the data.
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter es timates for LY3074828 will be calculated by  standard 
nonco mpart mental methods of analysis.
The primary  parameters for analysis will be AUC(0 -∞), AUC(0 -tlast), and C max for LY3074828.  
The secondary  param eter for analysis will be the time to maximum observe d drug concentration 
(tmax) of LY3074828.  Other noncompart mental param eters, such as half-life associated with the 
terminal rate constant ( t1/2), apparent total body clearance of drug calculated after extra -vascular 
administration (CL/F), and apparent vol ume of  distributi on during the terminal phase after 
extra -vascular administration (V z/F), may  be reported.
10.3.2.2. Pharmacokinetic Statistical Inference
The AUC(0 -∞), AUC(0 -tlast), and C max will be log-transformed and analyzed using alinear 
fixed -effects m odel.  The m odel will include device and injection locat ion as fixed effect s.  The 
dosing reg imen differences between Test and Reference arms will be back -transform ed to 
present the ratios of geometric LS means and the corresponding 90% CI.
The t maxof LY3074828 between Test and Reference arms will be analyzed using a Wilcoxon 
rank sum test.  Estimates of the median difference, 90% CIs, and p -values fro m the Wilcoxon 
rank sum test will be calculated.
Addit ional PK analyses may be conducted if deemed appropriate.
10.3.3. Pharmacodynamic Analyses
This sect ion is not applicable for this study.
10.3.4. Pharmacokinetic/Pharmacodynamic Analyses
This sect ion is not applicable for this study.
10.3.5. Evaluation of Immunogenicity
The frequency of format ion of antibodies to LY3074828 will be determined.  
Treatment -emergent ADAs are those that are induced or boosted by exposure to study drug, with 
a 4-fold or greater increase in t iter com pared to baseline if ADAs were detected at baseline, or a 
titer 2-fold greater than the minimum requ ired diluti on (1:10) if no ADAs were detected at 
baseline.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 44
LY3074828If a neutralization assay is performed, the frequency o f neutralizing ant ibodies will be 
determined.  The relat ionship between the presence (or absence) of ant ibodies and clinical 
param eters (AEs) will be assessed.  Likewise, the relat ionship between the presence of 
antibodies and the PK parameters orconcentrations of LY3074828 may be assessed if deemed 
appropriate.
10.3.6. Data Review During the Study
Data m ay be accessed and analyzed while the trial is o ngoing, but no changes to the study design 
are planned.  An assessment committee will not be formed.
Available safet y data will be reviewed at approximately Day  30of the l ast cohort dosed in order 
to revi ew emerging safet y and tol erabilit y data.
10.3.7. Interim A nalyses
Exploratory  interim analys is isscheduled to occur upon completion of all VAS assessments for 
all subjects .  The analys iswillinclude determination of the mean/median VAS scores and 
standard deviat ion, and categorical grouping of VAS data.  The VAS data from all 3 cohorts will 
be included in this interim analys is.  The purpose of the interim analys is is to examine the data 
priorto distribut ion to other teams wit hin Eli Lilly & Co mpany.  The analysi s will  be for internal 
purposes only and there i s no intent ion for the analys is to change the conduct of the trial. 
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 45
LY307482811. References
Cornelissen F, Asmawidjaja PS, Mus AM, Corneth O, Kikly K, Lubberts E. IL -23 dependent and 
independent stages of experimental arthrit is: no clinical effect of therapeutic IL -23p19 
inhibit ion in co llagen -induced arthrit is. PLoS One . 2013;8(2):e57553.
Crow J M. Therapeutics: silencing psoriasis. Nature. 2012;492(7429):S58 -S59.
Di Cesare A, Di  Megli o P, Nestl e FO. The IL -23/Th17 axis in the immunopathogenesis of 
psori asis. J Invest Dermatol. 2009;129(6):1339 -1350.
Lew W, Bowcock AM, Krueger JG. Psoriasis vulgar is: cutaneous lympho id tissue supports 
T-cell act ivation and “Type 1” inflammatory gene expressio n. Trends Immunol . 
2004;25(6):295 -305.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med . 2009;361(5):496 -509.
Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012;7:385 -422.
Ruutu M, Thomas G, Steck R, Degli -Espost i MA, Zinkernagel MS, Alexander K, Velasco J, 
Strutton G, Tran A, Benham H, Rehaume L, Wilson RJ, Kikly K, Davies J, Pettit AR, Brown 
MA, McGuckin MA, Tho mas R. β -glucan tri ggers spondylarthrit is and Crohn's disease -like 
ileitis in SKG mice. Arthritis Rheum . 2012;64(7):2211 -2222.
Sampson HA, Muñoz -Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown 
SG, Camargo CA Jr, Cy dulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, 
Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, 
Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the 
definit ion and management of anaphylaxi s: summary  report -Second National Institute of 
Allergy  and Infecti ous Disease/Food Allergy  and Anaphylaxis Network symposium. J Allergy 
Clin Immunol . 2006;117(2):391 -397.
Steinman L. A brief history  of T(H)17, the first major revisio n in the T(H)1/T(H)2 hypothesis of 
T cell -mediated tissue damage. Nat Med .2007;13(2):139 -145.
Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL -17 family cytokines and the expanding 
diversit y of effector T cell lineages. Annu Rev Immunol . 2007;25:821 -852.
Williamson A, Hogga rt B. Pain: a review o f three commo nly used pain rat ing scales. J Clin 
Nurs . 2005;14(7):798 -804.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 46
LY3074828Appendix 1. Abbreviations and Definitions
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 47
LY3074828Term Definition
ADA anti-drug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or diseas e temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
AI autoinjector
ALP alkaline phosphatase
ALT alanine aminotransferase
AUC area under the concentration versus time curve
AUC(0 -∞) area under the concentration versus time curve from time zero to infinity
AUC(0 -tlast) area under the concentration versus time curve from time zero to time t, where t is the last 
sample with a measurable concentration
BMI body mass index
CI confidence interval
CL/F apparent total body clearance of drug calculated after extra -vascular administration
Cmaxmaximum observed drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate .  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CP clinical pharmacologist
CRP clinical resea rch phy sician
CRU clinical research unit
ECG electrocardiogram
eCRF electronic case report form
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 48
LY3074828ED early  discontinuation
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
enter Subjects entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
GCP good clinical practice
GPS Global Patient Safety
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmoni sation
IFU Instructio ns for Use
IL-23 interleukin -23
informed consent A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular study, after having been informed of all aspects of the study that are relevant to 
the subject’s decision to participate.  Informed consent is documente d by means of a 
written, signed and dated informed consent form.  
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
product (IP)A pharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical study, including products already on the market when used or assembled 
(formulated or packaged) in a way different from the a uthorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
investigator A person responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
IRB institutional review board
ISR injection -site reaction
IV intravenous(ly)
LS least squares
open -label A study  in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 49
LY3074828randomize The process of assigning subjects/patients to an experimental group on a random basis .
PC product complaint
PFS pre-filled syringe
PK pharmacokinetic(s)
SAE serious adverse event
SC subcutaneous(ly)
screen The act of determining if an individual meets minimum requirements to become part of a
pool of potential candidates for participation in a clinical study.   
SUSARs suspected unexpected serious adverse reactions 
t1/2half-life associated with the terminal rate constant
TB tuberculosis
TBL total bilirubin
TE-ADA treatment -emergent anti -drug antibody
TEAE treatment -emergent adverse event:  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state , and does not necessarily have to have a causal relationship with this 
treatment .
Th T helper
tmaxtime to maximum observed drug concentration
ULN upper limit of normal
VAS visual analog scale
Vz/F apparent volume of distribution during the terminal phase after extra -vascular 
administration
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 50
LY3074828Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology a Clinical Chemistry a
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Calcium
Mean cell volume Phospho rus
Mean cell hemoglobin Glucose (random)
Mean cell hemoglobin concentration Blood urea nitrogen (BUN)
Leukocytes (WBC) Uric acid
Cell morphology Total cholesterol
Absolute counts of: Total protein
Neutrophils Albumin
Lymphocy tes Total bilirubin c
Monocytes Alkaline phosphatase (ALP)
Eosinophils Aspartate aminotransferase (AST)
Basophils Alanine aminotransferase (ALT)
Platelets Creatinine
Creatine phosphokinase (CPK) d
Urinalysis a Ethanol testing e
Specific gravity Urine drug screen e
pH QuantiFERON -TB Gold test a,f
Protein
Glucose Serology f
Ketones Hepatitis B surface antigen
Bilirubin Hepatitis C antibody
Urobilinogen HIV antibodies
Blood
Nitrite Serum Pregnancy test g,h
Microscopic examination of sediment b Hormone Panel
Follicle -stimulating hormone f,i
Abbreviations:  HIV = human immunodeficiency virus; RBC = red blood cells; TB = tuberculosis; WBC = white 
blood cells.
aResults will be validated by the local laboratory at the time of initial testing.
bIf clinically indicated, per investigator’s discret ion.
cIf total bilirubin is elevated, direct bilirubin and indirect bilirubin may be measured.
dNot collected routinely as part of clinical chemistry panel . Only collected when specified in Schedule of 
Activities (Section 2).
eUrine drug screen and ethanol level (determined via breath , blood ,or urine testing) will be performed locally at 
screening and on Day -1 dur ing admission to the clinical research unit.  May be repeated at the discretion of the 
investigator . 
fPerformed at screening only.
gFor all females at screening and on Day -1, and only  for women of childbearing potential at sampling time points 
thereafter.
hRefer to Section 2for specific sampling timing.
iTo confirm postmenopausal status .
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 51
LY3074828Appendix 3. Study  Governance, Regulatory  and Ethical 
Conside rations
Informed Consent
The invest igator is responsible for:
ensuring that the subject understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r parti cipat ion is vo luntary.
ensuring that informed consent is given by each subject or legal representative.  Thi s 
includes obtaining the appropriate signatures and dates on the informed consent form 
(ICF)prior to the performance of any  protocol  procedures and prior to the administr ation 
of investigational product.
answering any quest ions the subject may  have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the subject ’swillingness to 
continue his or her participat ion in the study .
providing a copy  of the ICF to the parti cipant or the participant’s legal representative and 
retaining a copy  on file .
Recruitment
Lilly or i ts desi gnee is responsible for the central recruit ment strategy  for pati ents.  Individual 
investigators may ha ve addit ional l ocal requirements or processes.   Study -specific recruit ment 
materi al should be approved by Lilly .
Ethical Review
The invest igator must give assurance that the institutional review board ( IRB) was properly 
constituted and convened as required by Internat ional Council for Harmonisation ( ICH)
guidelines and other applicable laws and regulations.
Docum entati on of  IRB approval o f the protocol  and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s).  All ICFs must be compliant with the ICH guideline 
on good clinical practice ( GCP ).
The study  site’s IRB(s) should be provided with the fo llowing:
the current Invest igator’ s Brochure and updates during the course of the study
ICF
relevan t curri cula vi tae.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 52
LY3074828Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with :
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences Internat ional Ethical Guidelines 
2)applicable ICH GCP Guidelines 
3)applicable laws and regulations .
Some of the obligat ions of the sponsor will be assigned to a third party  organizat ion.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the prot ocol accurately  describes the pl anned design and conduct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Final Report Signature
The invest igator or designee will sign the clinical study report for this study, indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
provi detraining to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the electronic case report fo rms 
(eCRFs ), and study  procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax
review and evaluate eCRF data and/or use standard computer edits to dete ct errors in data 
collect ion
conduct a qualit y review of the database .
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 53
LY3074828In addit ion, Lilly or its representatives willperiodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly an d/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable IRBs with direct access to the original source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.  
The p urpose and use of subject personal informat ion collected will be provided in a written 
docum ent to the subject by  the s ponsor .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued ifLilly  or its desi gnee , the invest igator, or the IRB
of the study  sitejudges it necessary for medical , safet y, regulatory , or oth er reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regul ations, and GCP.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 54
LY3074828Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained i n the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th subjects in consultation with Lilly or i ts desi gnee clinical research 
physician .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis C antibody
Hepatic Chemistry a Hepatitis E antibody, IgG
Total bilirubin Hepatitis E antibody, IgM
Conjugated bilirubin
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST Alkaline phosphatase isoenzymes a
GGT
CPK Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red 
blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/con firmation dependent on regulatory requirements and/or testing availability .
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 55
LY3074828Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .  
Protocol I6T-MC-AMAR Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a 22.5 1 22.5
Clinical laboratory tests a 12.5 5 62.5
Pharmacokinetics b 2 17 34
Immunogenicity a 10 5 50
Pregnancy tests 3.5 4 14
Pharmacogenetics 10 1 10
Total 193
Total for clinical purposes [rounded up to nearest 10 mL] 200
aAdditional samples may be drawn if needed for safety purposes.
bIncludes a potential 3 additio nal samples to be matched to additional immunogenicity samples (see 
Section 9.6.1 ).
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 56
LY3074828Appendix 6. Protocol A mendment I6T-MC-AMAR(a) 
Summary :  A Safety , Tolerability , and Pharmacokinetic 
Study  of Injections of LY3074828 Solution Using 
Investigational 1 -mL Pre -filled Sy ringes and 
Investigational 2 -mLAutoinjector in Healthy  Subjects 
Overview
Protocol  I6T-MC-AMAR [A Safet y, Tolerabili ty, and Pharm acokinetic Study  of Inject ions of 
LY3074828 Solut ion Using Invest igational 1 -mL Pre -filled Sy ringes and Investigational 
2-mLAutoi njector in Healthy Subjects] has been amended.  The new protocol is indicated by  
Amendment (a) and will be used to conduct the study  in place of any preceding version of the 
protocol .
The overall changes and rationale for the changes made to this protocol are as fo llows:
addition of  a footnote for creatine phosphokinase inthe clinical laboratory  tests in order 
to clarify  that i t will  only be assessed at the time points specified in the Schedule of 
Activities (ie, Day -1, 8, and 29 ) rather than at each time po int clinical laboratory tests are 
perform ed.
addition of  expl oratory  interim analyses ,for internal  use only ,toinform program  
decis ions of invest igational product development.
update to the order of priorit y in cases where several study  procedures are scheduled at 
the sam e time, to minimize the number of blood draws.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 57
LY3074828Revised Protocol Sections
Note: All deletions have been ident ified by strikethroughs .
All additions have been ident ified by the use of underscore .
2. Schedule of Activities (footnote)
Site shoul d schedule act ivities as appropriate.  In cases where several study  procedures are 
scheduled at the sam e time, fo llow this order of priority  for procedures:  pharm acokinet ic 
samples, clinical laboratory  tests, immunogenicit y sample, stored sample , ECG, vi tal signs, 
clinical laboratory  tests, pain assessment, inject ion-site assessment, immunogenic ity sample, 
stored sample, such that pharmacokinet ic sample collect ion occurs as close to the no minal 
collect ion time as possible.  
10.3.7. Interim Analyses
No interim analyses are planned for this study .  If an unplanned interim analysis is deemed 
necessary , the Lilly CP, CRP/investigator, or designee will consult with the appropriate medical 
director or desi gnee to determine if it is necessary  to am end the protocol .  Exploratory  interim 
analysis is scheduled to occur upon complet ion of all VAS asse ssments for all subjects.  The 
analysis will include determinat ion of the mean/median VAS scores and standard deviat ion, and 
categori cal grouping of VAS data.  The VAS data from all 3 cohorts will be included in this 
interim analysis.  The purpose of the i nterim analysis is to examine the data prior to distribution 
to other teams wit hin Eli Lilly & Co mpany.  The analysis will be for internal purposes only and 
there is no intention for the analysis to change the conduct of the trial.
I6T-MC-AMAR (a)Clinical Pharmacology Proto col Page 58
LY3074828Appendix 2. Clinical L aboratory Tests
Clinical Chemistry a
…
…
Creatine phosphokinase (CPK) d
Ethanol testing d e
Urine drug screen d e
QuantiFERON -TB Gold test a,e f
Serology e f
Hepatitis B surface antigen
Hepatitis C antibody
HIV antibodies
Serum Pregnancy test f g, h
Hormone Panel
Follicle -stimulating hormone e f, h i
…
dNot collected routinely as part of clinical chemistry panel . Only collected when specified in Schedule of 
Activities (Section 2).
d eUrine drug screen and ethanol level (determined via breath, blood, or urine testing) will be performed locally at 
screening and on Day -1 during admission to the clinical research unit.   May be repeated at the discretion of the 
investigator . 
e fPerformed at screening only.
f gFor all females at screening and on Day -1, and only  for women of childbearing potential at sampling time points 
thereafter.
g hRefer to Section 2for specific sampling timing.
h iTo confirm postmenopausal status.
Leo Document ID = e3ac71ff-f9d2-4015-8099-f5aba7b5ead7
Approver: 
Approval Date & Time: 13-Sep-2018 13:49:29 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 13-Sep-2018 14:39:30 GMT
Signature meaning: Approved
